Search Results - "Herrera, Alex F."

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma by Sehn, Laurie H, Herrera, Alex F, Flowers, Christopher R, Kamdar, Manali K, McMillan, Andrew, Hertzberg, Mark, Assouline, Sarit, Kim, Tae Min, Kim, Won Seog, Ozcan, Muhit, Hirata, Jamie, Penuel, Elicia, Paulson, Joseph N, Cheng, Ji, Ku, Grace, Matasar, Matthew J

“…Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, with limited treatment options. The…”
Get full text

Can we cure relapsed/refractory Hodgkin lymphoma without a stem cell transplant? by Mei, Matthew G, Herrera, Alex F

Get full text

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation by Davids, Matthew S., Kim, Haesook T., Costello, Caitlin, Herrera, Alex F., Locke, Frederick L., Maegawa, Rodrigo O., Savell, Alexandra, Mazzeo, Michael, Anderson, Adrienne, Boardman, Alexander P., Weber, Augustine, Avigan, David, Chen, Yi-Bin, Nikiforow, Sarah, Ho, Vincent T., Cutler, Corey, Alyea, Edwin P., Bachireddy, Pavan, Wu, Catherine J., Ritz, Jerome, Streicher, Howard, Ball, Edward D., Bashey, Asad, Soiffer, Robert J., Armand, Philippe

“…Programmed cell death-1 (PD-1)/programmed death ligand-1 blockade may potentially augment graft-vs-tumor effects following allogeneic hematopoietic cell…”
Get full text

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma by Zurko, Joanna, Ramdial, Jeremy, Shadman, Mazyar, Ahmed, Sairah, Szabo, Aniko, Iovino, Lorenzo, Tomas, Ana Alarcon, Sauter, Craig, Perales, Miguel-Angel, Shah, Nirav N, Acharya, Utkarsh H, Jacobson, Caron, Soiffer, Robert J, Wang, Trent, Komanduri, Krishna V, Jaglowski, Samantha, Kittai, Adam S, Denlinger, Nathan, Iqbal, Madiha, Kharfan-Dabaja, Mohamed A, Ayala, Ernesto, Chavez, Julio, Jain, Michael, Locke, Frederick L, Samara, Yazeed, Budde, Lihua E, Mei, Matthew G, Pia, Alexandra Della, Feldman, Tatyana, Ahmed, Nausheen, Jacobs, Ryan, Ghosh, Nilanjan, Dholaria, Bhagirathbhai, Oluwole, Olalekan O, Hess, Brian, Hassan, Ayesha, Kenkre, Vaishalee P, Reagan, Patrick, Awan, Farrukh, Nieto, Yago, Hamadani, Mehdi, Herrera, Alex F

“…Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage large B-cell lymphoma (LBCL) patients experiencing treatment failure after…”
Get full text

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation by Herrera, Alex F, Mei, Matthew, Low, Lawrence, Kim, Haesook T, Griffin, Gabriel K, Song, Joo Y, Merryman, Reid W, Bedell, Victoria, Pak, Christine, Sun, Heather, Paris, Tanya, Stiller, Tracey, Brown, Jennifer R, Budde, Lihua E, Chan, Wing C, Chen, Robert, Davids, Matthew S, Freedman, Arnold S, Fisher, David C, Jacobsen, Eric D, Jacobson, Caron A, LaCasce, Ann S, Murata-Collins, Joyce, Nademanee, Auayporn P, Palmer, Joycelynne M, Pihan, German A, Pillai, Raju, Popplewell, Leslie, Siddiqi, Tanya, Sohani, Aliyah R, Zain, Jasmine, Rosen, Steven T, Kwak, Larry W, Weinstock, David M, Forman, Stephen J, Weisenburger, Dennis D, Kim, Young, Rodig, Scott J, Krishnan, Amrita, Armand, Philippe

“…Purpose Double-hit lymphomas (DHLs) and double-expressor lymphomas (DELs) are subtypes of diffuse large B-cell lymphoma (DLBCL) associated with poor outcomes…”
Get full text

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data by Sehn, Laurie H., Hertzberg, Mark, Opat, Stephen, Herrera, Alex F., Assouline, Sarit, Flowers, Christopher R., Kim, Tae Min, McMillan, Andrew, Ozcan, Muhit, Safar, Violaine, Salles, Gilles, Ku, Grace, Hirata, Jamie, Chang, Yi Meng, Musick, Lisa, Matasar, Matthew J.

“…Polatuzumab vedotin plus bendamustine and rituximab (pola + BR) received regulatory approvals for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)…”
Get full text

Ibrutinib for the treatment of mantle cell lymphoma by Herrera, Alex F, Jacobsen, Eric D

“…Ibrutinib (PCI-32765)--a potent, covalent inhibitor of Bruton tyrosine kinase (BTK), an important kinase in the B-cell receptor signaling pathway--was recently…”
Get full text

Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma by Yi, Shuhua, Yan, Yuting, Jin, Meiling, Bhattacharya, Supriyo, Wang, Yi, Wu, Yiming, Yang, Lu, Gine, Eva, Clot, Guillem, Chen, Lu, Yu, Ying, Zou, Dehui, Wang, Jun, Phan, An T, Cui, Rui, Li, Fei, Sun, Qi, Zhai, Qiongli, Wang, Tingyu, Yu, Zhen, Liu, Lanting, Liu, Wei, Lyv, Rui, Sui, Weiwei, Huang, Wenyang, Xiong, Wenjie, Wang, Huijun, Li, Chengwen, Xiao, Zhijian, Hao, Mu, Wang, Jianxiang, Cheng, Tao, Bea, Silvia, Herrera, Alex F, Danilov, Alexey, Campo, Elias, Ngo, Vu N, Qiu, Lugui, Wang, Lili

“…Mantle cell lymphoma (MCL) is a phenotypically and genetically heterogeneous malignancy in which the genetic alterations determining clinical indications are…”
Get full text

Noncellular Immune Therapies for Non-Hodgkin Lymphoma by Herrera, Alex F., MD

“…Non-Hodgkin lymphomas (NHL) are a diverse group of diseases, encompassing mature B-cell, T-cell, and natural killer cell malignancies and ranging in behavior…”
Get full text

Impact of conditioning regimen intensity on the outcomes of peripheral T‐cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T‐cell lymphoma patients undergoing allogeneic transplant by Savani, Malvi, Ahn, Kwang W., Chen, Yue, Ahmed, Sairah, Cashen, Amanda F., Shadman, Mazyar, Modi, Dipenkumar, Khimani, Farhad, Cutler, Corey S., Zain, Jasmine, Brammer, Jonathan E., Rezvani, Andrew R., Fenske, Timothy S., Sauter, Craig S., Kharfan‐Dabaja, Mohamed A., Herrera, Alex F., Hamadani, Mehdi

“…Summary There have been no large studies comparing reduced‐intensity/non‐myeloablative conditioning (RIC/NMA) to myeloablative conditioning (MAC) regimens in…”
Get full text

Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma by Kambhampati, Swetha, Saumoy, Monica, Schneider, Yecheskel, Serrao, Steve, Solaimani, Pejman, Budde, Lihua Elizabeth, Mei, Matthew G., Popplewell, Leslie L., Siddiqi, Tanya, Zain, Jasmine, Forman, Stephen J., Kwak, Larry W., Rosen, Steven T., Danilov, Alexey V., Herrera, Alex F., Thiruvengadam, Nikhil R.

“…•Second-line axi-cel is provisionally cost-effective in selected primary refractory/early relapsed DLBCL patients at a WTP of $100 000 per QALY.•The…”
Get full text

Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study by Flowers, Christopher R, Matasar, Matthew J, Herrera, Alex F, Hertzberg, Mark, Assouline, Sarit, Demeter, Judit, McMillan, Andrew, Mehta, Amitkumar, Opat, Stephen, Trnňný, Marek, Musick, Lisa, Hirata, Jamie, Yang, Annie, Sehn, Laurie H

“…Follicular lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma. Despite treatment advances that have improved outcomes for patients with…”
Get full text

Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches by Hanel, Walter, Herrera, Alex F, Epperla, Narendranath

“…The treatment landscape of classical Hodgkin lymphoma (cHL) has undergone significant changes over the past 20 years. Gradual improvements have been made in…”
Get full text

Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit by Mei, Matthew, Hamadani, Mehdi, Ahn, Kwang W, Chen, Yue, Kharfan-Dabaja, Mohamed A, Sauter, Craig, Herrera, Alex F

Get full text

Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy by Mercadal, Santiago, Ahn, Kwang Woo, Allbee-Johnson, Mariam, Ganguly, Siddhartha, Geethakumari, Praveen Ramakrishnan, Hong, Sanghee, Malone, Adriana, Murthy, Hemant, Pawarode, Attaphol, Sica, Alejandro R, Solh, Melhem, Ustun, Celalettin, Shadman, Mazyar, Sauter, Craig S, Hamadani, Mehdi, Herrera, Alex F, Lee, Catherine J

Get full text

Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma by Godfrey, James, Mei, Matthew, Chen, Lu, Song, Joo Y, Bedell, Victoria, Budde, Elizabeth, Armenian, Saro, Puverel, Sandrine, Nikolaenko, Liana, Chen, Robert, Daniels, Shari, Kennedy, Neena, Peters, Lacolle, Rosen, Steven T, Forman, Stephen J, Popplewell, Leslie L, Kwak, Larry W, Herrera, Alex F

“…Outcomes after programmed death-1 (PD-1) blockade in B-cell lymphomas are disappointing with few durable responses. Histone deacetylase inhibitors exhibit…”
Get full text

Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma by Othman, Tamer, Frankel, Paul, Allen, Pamela, Popplewell, Leslie L, Shouse, Geoffrey, Siddiqi, Tanya, Danilov, Alexey V, Ruel, Nora, Daniels, Shari, Peters, Lacolle, Khoo, Stella, Rosen, Steven T, Sharon, Elad, Villalona-Calero, Miguel, Ruel, Christopher, Tuscano, Joseph, Herrera, Alex F

“…Patients with relapsed/refractory (R/R) transformed diffuse large B-cell lymphoma (DLBCL) from indolent B-cell lymphomas, including Richter transformation…”
Get full text

Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma by Song, Joo Y, Nwangwu, Mary, He, Ting-Fang, Zhang, Weiwei, Meawad, Hany, Bedell, Victoria, Murata-Collins, Joyce, Skrabek, Pamela, Nasr, Michel R, Scott, David, Godfrey, James, Lee, Peter, Chan, Wing C, Weisenburger, Dennis D, Perry, Anamarija M, Herrera, Alex F

“…The tumor microenvironment (TME) is important in the pathogenesis and prognosis of lymphoma. Previous studies have demonstrated that features of the diffuse…”
Get full text

Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy by Crombie, Jennifer L, Jacobson, Caron A, Redd, Robert, Shouse, Geoffrey, Herrera, Alex F, Chow, Victor A, Gauthier, Jordan, Mullane, Erin, Cahill, Kirk, Kline, Justin, Romancik, Jason, Cohen, Jonathon B, Saucier, Anna, Houot, Roch, Armand, Philippe, Hess, Brian

Get full text

PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL by Dreger, Peter, Sureda, Anna, Ahn, Kwang Woo, Eapen, Mary, Litovich, Carlos, Finel, Herve, Boumendil, Ariane, Gopal, Ajay, Herrera, Alex F., Schmid, Christoph, Diez-Martin, José Luis, Fuchs, Ephraim, Bolaños-Meade, Javier, Gooptu, Mahasweta, Al Malki, Monzr M., Castagna, Luca, Ciurea, Stefan O., Dominietto, Alida, Blaise, Didier, Ciceri, Fabio, Tischer, Johanna, Corradini, Paolo, Montoto, Silvia, Robinson, Stephen, Gülbas, Zafer, Hamadani, Mehdi

“…This study retrospectively compared long-term outcomes of nonmyeloablative/reduced intensity conditioning (NMC/RIC) allogeneic hematopoietic cell…”
Get full text